最新报道:Nasdaq will delist Windtree Therapeutics (WINT) for failing to maintain a minimum $1 share price, with trading suspension effective August 21, 2025. The biotech firm, which recently invested heavily in BNB tokens, has seen its stock plummet over 99% this year to $0.11. Despite the delisting, CEO Jed Latkin confirmed the company will continue its reporting obligations.